Arrowhead Pharmaceuticals (NASDAQ: ARWR) director granted 7,819 RSUs

Rhea-AI Filing Summary

Arrowhead Pharmaceuticals director reports new stock award. A board member of Arrowhead Pharmaceuticals received 7,819 shares of common stock on 12/16/2025 through restricted stock units. These shares were acquired at a stated price of $0, reflecting an equity grant rather than an open-market purchase. After this award, the director beneficially owns 43,600 shares of Arrowhead common stock directly.

The 7,819 shares represent underlying restricted stock units that will vest in a single installment on the first anniversary of the grant date, as long as the director continues to serve the company through that date. This filing documents the equity-based compensation granted to the director and updates the total number of shares reported as beneficially owned.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

OLUKOTUN ADEOYE Y

(Last) (First) (Middle)

177 E COLORADO BLVD

STE 700

(Street)

PASADENA CA 91105

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ARROWHEAD PHARMACEUTICALS, INC. [ ARWR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/16/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/16/2025		A		7,819(1)	A	$0	43,600	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares underlying restricted stock units, which shares will vest in one installment on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on such date.

Remarks:

	/s/Adeoye Olukotun	12/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Arrowhead Pharmaceuticals (ARWR) disclose?

Arrowhead Pharmaceuticals disclosed that a director acquired 7,819 shares of its common stock on 12/16/2025 through a restricted stock unit award, reported at a price of $0 per share.

Who is the reporting person in this Arrowhead Pharmaceuticals (ARWR) filing?

The reporting person is a director of Arrowhead Pharmaceuticals, as indicated in the relationship section of the filing.

How many Arrowhead Pharmaceuticals (ARWR) shares does the director own after this transaction?

Following the reported transaction, the director beneficially owns 43,600 shares of Arrowhead Pharmaceuticals common stock in direct ownership.

What type of equity award did the Arrowhead Pharmaceuticals (ARWR) director receive?

The director received an award of restricted stock units representing 7,819 shares of Arrowhead Pharmaceuticals common stock.

When do the restricted stock units for Arrowhead Pharmaceuticals (ARWR) vest?

The 7,819 restricted stock units will vest in one installment on the first anniversary of the grant date, subject to the director’s continued service with Arrowhead Pharmaceuticals on that date.

Was this Arrowhead Pharmaceuticals (ARWR) transaction a market purchase?

No. The filing shows the director acquired 7,819 shares at a price of $0, indicating an equity grant via restricted stock units rather than a market purchase.